Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis?

R C Dale, J A Branson

The differential diagnosis of CNS white matter disease is broad, and can be divided into vascular, metabolic, infective, or inflammatory aetiologies. Isolated inflammatory disorders of the CNS are often associated with demyelination, and the two terms (inflammatory and demyelinating) are often used in conjunction. When the disease is monophasic, the term acute disseminated encephalomyelitis (ADEM) is used.1 ADEM typically occurs as a post-infectious phenomenon, and by definition, must be an isolated (monophasic) episode. If a relapse occurs shortly after the ADEM presentation in association with a further infection or steroid withdrawal, the term MDEM (multiphasic disseminated encephalomyelitis) is used. When there are relapses or progressive disease, the term multiple sclerosis (MS) is used (for full recommended diagnostic criteria for multiple sclerosis refer to McDonald and colleagues2).

The diagnostic differentiation between acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) is important mainly for prognostic reasons. Children with ADEM are generally expected to do well, whereas children with MS are more likely to develop significant disability. The ability to reduce MS disease progression with immunomodulatory drugs further emphasises the importance of a prompt and accurate diagnosis. Over the last five years, there have been a number of large series reporting the clinical features of paediatric ADEM, MS, and the differences between these.3–6 A large follow up series of children with a first episode of central nervous system (CNS) inflammatory demyelination showed a much higher rate of progression to multiple sclerosis than previously reported.4 The clinical features of these treatable disorders are therefore the subject of this review. It must be stated from the outset that the clinical and laboratory differences between ADEM and MS are trends only, and do not provide rigid diagnostic criteria.

THE DIAGNOSTIC DILEMMA

The research purpose of this review is to address the diagnostic dilemma presented in fig 1. Are ADEM and MS distinct clinical disorders, or part of a disease spectrum? By definition, both ADEM and MS cases must manifest disseminated disease of the CNS (more than one clinical or radiological site). Diseases isolated to specific areas of the CNS (isolated optic neuritis, transverse myelitis, and brain stem dysfunction) are considered distinct from both ADEM and MS (clinically and prognostically), and will not be discussed in this review.3–9

DEMographics

Monophasic ADEM is more common in children, whereas MS is more common in adults. Between 2.7% and 4.4% of MS presentations occur in children less than 16 years of age.2 Mikaeloff et al showed a mean age of 7.1 years and 12.0 years in paediatric ADEM and MS patients respectively.6 Most reports of ADEM have described a peak incidence in children of 3–10 years.3–4 An adolescent presenting with a first demyelinating event is more likely to develop multiple sclerosis than a younger child.1,3 Most series of ADEM have failed to show a sex predominance, although some series show a mild male predominance.3,9 By contrast, females are more predisposed to develop multiple sclerosis, particularly in adolescence and adulthood.9

Precipitating infection and seasonality

As would be expected from an infection mediated syndrome, ADEM most commonly presents during winter and spring.3–5 Between 51% and 74% of ADEM patients have a history of a precipitating infection with a mean latency of approximately two weeks.3–6,8 A large number of infections may precipitate ADEM, although isolation of a specific agent is uncommon (classic infectious precipitants include measles, Epstein-Barr virus, mycoplasma, and group A streptococcus).3,8 Although infections may precipitate an MS relapse, the association with infections and seasonality is less pronounced (only 16% of patients have an infection in the preceding month).9

Neurological symptoms and signs

Patients with ADEM are more likely to present with encephalopathy and may be initially diagnosed as having viral encephalitis.1,3 ADEM patients commonly have headache, vomiting,
drowsiness, and meningism. These symptoms are uncommon in MS. Seizures occur in 13–35% of ADEM patients, although they are seldom as problematic as those seen in viral encephalitis, which is more likely to involve cortical grey matter. By contrast, seizures are considered rare in multiple sclerosis.

As both ADEM and MS are disseminated disorders of the CNS, a broad range of neurological signs is possible. Pyramidal, cerebellar, and brain stem signs are common in both disorders. Encephalopathy with depressed consciousness and altered sensorium is more common in ADEM (45–75%) than in MS (13–15%). Optic neuritis (ON) occurs in both ADEM and MS. ON is frequently bilateral in ADEM, whereas it is typically unilateral in MS.

Morrissey’s study also noted the importance of considering Leber’s hereditary optic neuropathy (a mitochondrial mutation) in children presenting with bilateral optic neuritis/neuropathy. As ADEM tends to be more florid, there are frequently multiple symptoms and signs (polysymptomatic presentation), whereas symptoms and signs are commonly isolated (monosymptomatic) in MS.

**BLOOD AND CSF FEATURES**

In keeping with an explosive post-infectious phenomenon, patients with ADEM frequently have raised inflammatory markers (white cell count, erythrocyte sedimentation rate) and lymphopenia. The CSF more commonly shows an increased protein and cell count (lymphocytosis) in ADEM, although normal and abnormal CSF findings occur in both ADEM and MS. One of the most discriminating CSF findings is the presence of intrathecal synthesis of oligoclonal bands (oligoclonal IgG in CSF but not in serum), which occurs in 40–95% of MS patients, but only 0–29% of ADEM patients. Indeed, some authorities would seriously question the diagnosis of MS if there were not intrathecal synthesis of oligoclonal IgG.

**MAGNETIC RESONANCE NEUROIMAGING**

MRI is an essential part of the investigation of ADEM and MS. Both ADEM and MS show disseminated inflammatory lesions throughout the CNS (although predominantly in the white matter). Occasionally, large mass-like lesions occur and may require a biopsy. A number of studies have reported imaging differences between childhood ADEM and MS. The lesions in ADEM often have poorly defined margins, whereas MS lesions have well defined “plaque-like” margins. There are also differences in the lesion sites. Periaqueductal, corpus callosum, and periventricular white matter lesions are characteristic of MS. By contrast, in ADEM the lesions tend to be in the deeper white matter with periventricular sparing (only 29–60% of ADEM patients have periventricular lesions) (fig 2). When the spinal cord is involved in ADEM, the lesion is typically large, swollen, and thoracic. The spinal cord lesions in MS are typically smaller, more discrete, and cervical. In addition, although the white matter is classically involved in both disorders, the grey matter (both cortical and deep grey/basal ganglia) is frequently involved in ADEM (in contrast to MS).

Post-streptococcal ADEM shows particular predisposition to basal ganglia lesions. A recent MRI study of 116 children with a first episode of inflammatory demyelination showed that perpendicular corpus callosum lesions and the sole presence of well defined lesions were the most specific predictive factors for relapse (although they had a low sensitivity).

Follow up MRI is useful in ADEM/MS differentiation. As would be expected, new lesions should not occur in ADEM (0–9% of ADEM patients have new lesions on follow up). The original lesions in ADEM completely resolve in 27–55% of ADEM patients, although more typically (45–64%) the lesions only partially resolve. By contrast, new lesions in MS are anticipated. The timing of repeat scanning is important, as too hasty a repeat scan may cause confusion if the patient is still in the acute/subacute phase. A lag time of six months after presentation would be appropriate for repeat scanning (when clinically indicated).
A recent important study of French children (n = 296) who suffered one episode of acute CNS inflammatory demyelination has not been thoroughly tested in childhood MS. It is prudent to use 10–30 mg/kg/day intravenous methylprednisolone (maximum 1 g) for three days, although some clinicians use oral prednisolone, or even defer treatment if the patient is spontaneously improving.3–6 Studies have shown that a tapered course of oral prednisolone (over 2–6 weeks) reduces the chance of early onset relapse—that is, MDEM (although these studies were retrospective).3 22 Prophylactic immunomodulation to prevent relapses in MS has been thoroughly tested in childhood MS. It is prudent for patients to remain on antivirals and antibiotics until viral/bacterial encephalitis can be excluded.5 10

OUTCOME

A recent important study of French children (n = 296) who suffered one episode of acute CNS inflammatory demyelination found a higher risk of progression to multiple sclerosis than previously reported (57%).8 This study has highlighted the need for caution in counselling parents regarding the risk of further events.

The outcome in ADEM is often good with 57–81% of patients making a complete recovery.3 5 21 In children who have suffered one episode of inflammatory demyelination, adverse prognostic factors for irreversible disability include: sequelae after the first episode, a polysymptomatic presentation, progressive evolution, and the number of relapses in the first two years.7 24 27

CONCLUSION

The recent published reports of ADEM and MS in children have highlighted some differences between the two conditions, which are reviewed in fig 3. It must be reiterated that these features are trends only, and there remains no diagnostic test for multiple sclerosis. Despite the significant advances in our understanding of the pathogenesis of inflammatory demyelinating CNS disorders, the only truly reliable diagnostic test remains time.

ACKNOWLEDGEMENTS

RCD has a training fellowship awarded by Action Medical Research and the Barnwood House Trust. We would like to thank Gavin Giovannoni for his support.

Authors’ affiliations

R C Dale, J A Branson, Great Ormond Street Hospital NHS Trust and Institute of Child Health, London, UK

Competing interests: none declared

REFERENCES


German etanercept registry for JIA patients

Etanercept, an anti-tumour necrosis factor α drug, has been approved and licensed for the treatment of active, treatment resistant, polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 years or older. An etanercept registry was begun in January 2001 by paediatric rheumatologists in Germany and Austria, and data from the first 3 months of the registry have been reported (G Horneff and colleagues. *Annals of the Rheumatic Diseases* 2004;63:1638–44).

Up to the end of October 2003 data had been collected on 322 patients from 36 centres. All had failed to respond to methotrexate before starting etanercept and they had been treated with etanercept for up to 48 months. Half of the patients had either systemic onset JIA (21%) or seronegative polyarticular JIA (29%). Twelve per cent had seropositive polyarticular JIA and 17% extended oligoarticular JIA. The remaining 21% had persistent oligoarticular JIA, enthesitis and arthritis JIA subtype, psoriasis and arthritis JIA subtype, or unclassified JIA. Patients with systemic onset JIA had more severe disease. A therapeutic effect of etanercept was documented at 1 month and increased throughout the first year. Overall, a 70% improvement was achieved in 30% at 1 month and 54% at 12 months. A 50% improvement was achieved in 54% at 1 month and 71% at 12 months. Among patients with systemic onset JIA the 70% improvement rates were 11% at 1 month and around 30% at 12 months, and the corresponding 50% improvement rates were 33% and 39%. Among 66 patients with systemic onset JIA 14 (21%) discontinued etanercept because of lack of effectiveness. Among 256 patients with non-systemic disease 11 (4%) stopped treatment because it was ineffective. Complete remission occurred in 26% of patients overall and in 13% of those with systemic onset disease. Treatment was stopped because of disease remission in 14 patients. Six of these had a relapse after 1–11 months. Re-treatment in five patients was successful. Sixty-nine adverse events were reported in 56 patients. Eleven patients stopped treatment because of an adverse event—influenza in three patients. Twelve adverse events were judged to be severe. The most common adverse events were local skin reaction (7), raised liver enzymes (7), and itching and a rash (6). Twenty patients had a variety of infections, the most serious of which was pneumonia, requiring mechanical ventilation. One patient developed central nervous system demyelination. Demyelination has been reported in three patients with JIA, and 17 with other forms of arthritis, on treatment with either etanercept or infliximab. The authors of this paper suggest performing MRI scans of the central nervous system in selected patients.

Etanercept is effective treatment for patients with refractory JIA. Improvement occurs within the first month of treatment and the rate and degree of improvement increase throughout the first year. Patients with systemic onset disease respond less well. The treatment is well tolerated on the whole.